Our Study

Passionately Committed to Patients

Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. The evaluation of the safety and efficacy of our investigational medicines in clinical trials is a critical component of the development process. We appreciate the role of volunteers who enroll in clinical trials, because they help us better understand the potential benefits and risks of our investigational therapies.


Cypress Study  –  A Phase 3, multi-center, randomized withdrawal and long-term extension study of ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in participants with multiple system atrophy (MSA).

Study Website

For more information on the Cypress Study, please call (650) 808-3737 or email us (cypress@theravance.com) and someone from our study team will respond as soon as we can. Please be sure to provide your contact information, as well as the nature of your interest/inquiry and whether you are a patient, caregiver or a healthcare provider.

Thank you for your interest!

Ampreloxetine Presented at the 33rd International Symposium on the Autonomic Nervous System

November 2-5, 2022; Sheraton Maui, Hawaii

Theravance AAS Logo

Biaggioni I, et al. Abstract 34  | Virtual Poster 106

A phase 3, 22-week, multi-center, randomized withdrawal study of ampreloxetine in treating symptomatic nOH

View Presentation


Kaufmann H, et al. Abstract 33  | Virtual Poster 117

Blood pressure and pharmacodynamic response of ampreloxetine, a norepinephrine reuptake inhibitor, in patients with symptomatic nOH

View Presentation


Freeman R, et al. Abstract 30  | Virtual Poster 4

Longitudinal analysis of ampreloxetine for the treatment of symptomatic nOH in subset of patients with MSA

View Presentation